Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 262

1.

Chameleons everywhere.

Sprenger K, Furrer H.

BMJ Case Rep. 2014 Nov 24;2014. pii: bcr2014205608. doi: 10.1136/bcr-2014-205608.

PMID:
25422329
[PubMed - in process]
2.

AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be.

Gisler V, Kraus D, Nemeth J, Lecompte MT, Merz L, Stoeckle M, Schmid P, Bernasconi E, Weber R, Cavassini M, Calmy A, Elzi L, Furrer H.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19621. doi: 10.7448/IAS.17.4.19621. eCollection 2014.

PMID:
25394125
[PubMed - in process]
Free PMC Article
3.

The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe.

Mocroft A, Ryom L, Lapadula G, Reiss P, Blaxhult A, Furrer H, Kutsyna G, Gatell J, Begovac J, Kirk O, Lundgren J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19561. doi: 10.7448/IAS.17.4.19561. eCollection 2014.

PMID:
25394068
[PubMed - in process]
Free PMC Article
4.

Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America.

Efsen AM, Schultze A, Post F, Panteleev A, Furrer H, Miller R, Skrahin A, Losso MH, Toibaro J, Girardi E, Miro J, Bruyand M, Obel N, Caylá J, Podlekareva D, Lundgren J, Mocroft A, Kirk O.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19505. doi: 10.7448/IAS.17.4.19505. eCollection 2014.

PMID:
25394014
[PubMed - in process]
Free PMC Article
5.

In vitro activity of clinically implemented β-lactams against Aerococcus urinae: presence of non-susceptible isolates in Switzerland.

Lupo A, Guilarte YN, Droz S, Hirzel C, Furrer H, Endimiani A.

New Microbiol. 2014 Oct;37(4):563-6. Epub 2014 Oct 1.

PMID:
25387295
[PubMed - in process]
Free Article
6.

Tracking a Tuberculosis Outbreak Over 21 Years: Strain-Specific Single-Nucleotide Polymorphism Typing Combined With Targeted Whole-Genome Sequencing.

Stucki D, Ballif M, Bodmer T, Coscolla M, Maurer AM, Droz S, Butz C, Borrell S, Längle C, Feldmann J, Furrer H, Mordasini C, Helbling P, Rieder HL, Egger M, Gagneux S, Fenner L.

J Infect Dis. 2014 Oct 30. pii: jiu601. [Epub ahead of print]

PMID:
25362193
[PubMed - as supplied by publisher]
7.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.

Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ; on behalf of the CHAIN Minority HIV-1 Variants Working Group.

J Antimicrob Chemother. 2014 Oct 21. pii: dku426. [Epub ahead of print]

PMID:
25336166
[PubMed - as supplied by publisher]
Free Article
8.

High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia- a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors.

Kuenzli E, Jaeger VK, Frei R, Neumayr A, DeCrom S, Haller S, Blum J, Widmer AF, Furrer H, Battegay M, Endimiani A, Hatz C.

BMC Infect Dis. 2014 Oct 1;14:528. doi: 10.1186/1471-2334-14-528.

PMID:
25270732
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients.

Bibert S, Wojtowicz A, Taffé P, Manuel O, Bernasconi E, Furrer H, Günthard HF, Hoffmann M, Kaiser L, Osthoff M, Cavassini M, Bochud PY; Swiss HIV Cohort Study.

AIDS. 2014 Aug 24;28(13):1885-9. doi: 10.1097/QAD.0000000000000379.

PMID:
25259701
[PubMed - in process]
10.

Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study.

Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Vose JM, Xicoy B, Ribera JM; for the HIV-Associated Hodgkin Lymphoma in the cART Era Study Group.

Cancer. 2014 Sep 23. doi: 10.1002/cncr.29066. [Epub ahead of print]

PMID:
25251326
[PubMed - as supplied by publisher]
11.

Sexually transmitted infections in HIV-infected people in Switzerland: cross-sectional study.

Sprenger K, Evison JM, Zwahlen M, Vogt CM, Elzi MV, Hauser C, Furrer H, Low N; Swiss HIV Cohort Study.

PeerJ. 2014 Aug 26;2:e537. doi: 10.7717/peerj.537. eCollection 2014.

PMID:
25237598
[PubMed]
Free PMC Article
12.

Emergence of Klebsiella pneumoniae co-producing NDM-1, OXA-48, CTX-M-15, CMY-16, QnrA and ArmA in Switzerland.

Seiffert SN, Marschall J, Perreten V, Carattoli A, Furrer H, Endimiani A.

Int J Antimicrob Agents. 2014 Sep;44(3):260-2. doi: 10.1016/j.ijantimicag.2014.05.008. Epub 2014 Jun 23.

PMID:
25123809
[PubMed - in process]
13.

[HIV-associated non-AIDS conditions].

Hasse B, Bernasconi E, Furrer H, Eyer MM, Kovari H.

Ther Umsch. 2014 Aug;71(8):483-9. doi: 10.1024/0040-5930/a000541. Review. German.

PMID:
25093313
[PubMed - indexed for MEDLINE]
14.

[Treatment and prevention of opportunistic infections].

Staehelin C, Elzi L, Weber R, Furrer H.

Ther Umsch. 2014 Aug;71(8):475-82. doi: 10.1024/0040-5930/a000540. Review. German.

PMID:
25093312
[PubMed - indexed for MEDLINE]
15.

[Antiretroviral therapy].

von Braun A, Furrer H, Battegay M, Calmy A, Cavassini M, Vernazza P, Bernasconi E, Weber R, Günthard HF.

Ther Umsch. 2014 Aug;71(8):461-8. doi: 10.1024/0040-5930/a000538. Review. German.

PMID:
25093310
[PubMed - indexed for MEDLINE]
16.

Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.

Metzner KJ, Scherrer AU, von Wyl V, Böni J, Yerly S, Klimkait T, Aubert V, Furrer H, Hirsch HH, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard HF; Swiss HIV Cohort Study.

AIDS. 2014 Sep 24;28(15):2231-9. doi: 10.1097/QAD.0000000000000397.

PMID:
25036184
[PubMed - in process]
17.

Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study.

Boillat-Blanco N, Darling KE, Schoni-Affolter F, Vuichard D, Rougemont M, Fulchini R, Bernasconi E, Aouri M, Clerc O, Furrer H, Günthard HF, Cavassini M; the Swiss HIV Cohort Study.

Antivir Ther. 2014 Jun 25. doi: 10.3851/IMP2815. [Epub ahead of print]

PMID:
24964403
[PubMed - as supplied by publisher]
18.

Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.

Wang Q, Young J, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Furrer H, Fehr J, Bucher HC, Battegay M; Swiss HIV Cohort Study.

HIV Clin Trials. 2014 May-Jun;15(3):92-103. doi: 10.1310/hct1503-92.

PMID:
24947533
[PubMed - indexed for MEDLINE]
19.

Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study.

Schäfer J, Young J, Bernasconi E, Ledergerber B, Nicca D, Calmy A, Cavassini M, Furrer H, Battegay M, Bucher H; Swiss HIV Cohort Study.

HIV Med. 2015 Jan;16(1):3-14. doi: 10.1111/hiv.12165. Epub 2014 May 8.

PMID:
24809704
[PubMed - in process]
20.

The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.

Young J, Wang Q, Fux CA, Bernasconi E, Furrer H, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC; Swiss HIV Cohort Study.

HIV Med. 2014 Sep;15(8):505-10. doi: 10.1111/hiv.12149. Epub 2014 Mar 18.

PMID:
24641488
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk